Jack A. Khattar - Aug 8, 2022 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role
President, CEO, Director
Signature
/s/ Timothy C. Dec, as attorney-in-fact
Stock symbol
SUPN
Transactions as of
Aug 8, 2022
Transactions value $
-$3,709,403
Form type
4
Date filed
8/9/2022, 05:25 PM
Previous filing
Jun 15, 2022
Next filing
Aug 10, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SUPN Common Stock Options Exercise $0 +192K +30.61% $0.00 819K Aug 8, 2022 Direct F1
transaction SUPN Common Stock Sale -$3.39M -108K -13.17% $31.40 711K Aug 8, 2022 Direct F1, F2
transaction SUPN Common Stock Sale -$322K -10K -1.41% $32.11 701K Aug 8, 2022 Direct F1, F3
holding SUPN Common Stock 1.05M Aug 8, 2022 By the KBT Trust
holding SUPN Common Stock 4K Aug 8, 2022 By son F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SUPN Employee Stock Option (Right to Buy) Options Exercise $0 -192K -64% $0.00 108K Aug 8, 2022 Common Stock 192K $7.90 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.950 to $31.950, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.960 to $32.535, inclusive. The reporting person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
F4 The Reporting Person disclaims beneficial ownership of the shares held by his son, who shares the Reporting Person's household, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose.
F5 The option vested in four equal annual installments beginning on February 5, 2014.